CN110801488A - Combined prebiotics particle for regulating brain and intestine axis polysaccharide and preparation method and application thereof - Google Patents
Combined prebiotics particle for regulating brain and intestine axis polysaccharide and preparation method and application thereof Download PDFInfo
- Publication number
- CN110801488A CN110801488A CN201911176424.2A CN201911176424A CN110801488A CN 110801488 A CN110801488 A CN 110801488A CN 201911176424 A CN201911176424 A CN 201911176424A CN 110801488 A CN110801488 A CN 110801488A
- Authority
- CN
- China
- Prior art keywords
- extract
- lily
- polysaccharide
- brain
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 71
- 239000002245 particle Substances 0.000 title claims abstract description 51
- 210000004556 brain Anatomy 0.000 title claims abstract description 43
- 150000004676 glycans Chemical class 0.000 title claims abstract description 41
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 41
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 41
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 39
- 210000000936 intestine Anatomy 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 241000234435 Lilium Species 0.000 claims abstract description 88
- 239000000284 extract Substances 0.000 claims abstract description 88
- 230000000968 intestinal effect Effects 0.000 claims abstract description 47
- 235000019206 astragalus extract Nutrition 0.000 claims abstract description 40
- 239000009636 Huang Qi Substances 0.000 claims abstract description 34
- 239000008187 granular material Substances 0.000 claims abstract description 32
- 235000006533 astragalus Nutrition 0.000 claims abstract description 27
- 241001061264 Astragalus Species 0.000 claims abstract description 25
- 210000004233 talus Anatomy 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 22
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 21
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 21
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 19
- 229920002472 Starch Polymers 0.000 claims abstract description 18
- 239000008107 starch Substances 0.000 claims abstract description 18
- 235000019698 starch Nutrition 0.000 claims abstract description 18
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 16
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000007873 sieving Methods 0.000 claims abstract description 16
- 239000000811 xylitol Substances 0.000 claims abstract description 16
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 16
- 229960002675 xylitol Drugs 0.000 claims abstract description 16
- 235000010447 xylitol Nutrition 0.000 claims abstract description 16
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 15
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 15
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 15
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 15
- 239000001509 sodium citrate Substances 0.000 claims abstract description 15
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 15
- 238000001035 drying Methods 0.000 claims abstract description 9
- 229960001790 sodium citrate Drugs 0.000 claims abstract description 9
- 235000011083 sodium citrates Nutrition 0.000 claims abstract description 9
- 229940032147 starch Drugs 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims description 25
- 238000000605 extraction Methods 0.000 claims description 25
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 22
- 206010022437 insomnia Diseases 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 208000010877 cognitive disease Diseases 0.000 claims description 16
- 239000007779 soft material Substances 0.000 claims description 16
- 238000003809 water extraction Methods 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 241000894006 Bacteria Species 0.000 abstract description 20
- 230000009286 beneficial effect Effects 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- 210000005036 nerve Anatomy 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 230000008093 supporting effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 36
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 22
- 239000006228 supernatant Substances 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 14
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 208000036649 Dysbacteriosis Diseases 0.000 description 10
- 208000027244 Dysbiosis Diseases 0.000 description 10
- 230000007140 dysbiosis Effects 0.000 description 10
- 241001591005 Siga Species 0.000 description 9
- 229940047169 astragalus root extract Drugs 0.000 description 8
- 239000002858 neurotransmitter agent Substances 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000000971 hippocampal effect Effects 0.000 description 7
- 230000009102 absorption Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 description 5
- 210000003405 ileum Anatomy 0.000 description 5
- 229960001595 lincomycin hydrochloride Drugs 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 230000003959 neuroinflammation Effects 0.000 description 5
- 238000010298 pulverizing process Methods 0.000 description 5
- 230000007958 sleep Effects 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000008451 emotion Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000008447 perception Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 3
- 241000045403 Astragalus propinquus Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 210000000105 enteric nervous system Anatomy 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000007087 memory ability Effects 0.000 description 3
- 230000008897 memory decline Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 208000020685 sleep-wake disease Diseases 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000037208 balanced nutrition Effects 0.000 description 2
- 235000019046 balanced nutrition Nutrition 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 240000008058 Lilium brownii Species 0.000 description 1
- 235000015982 Lilium brownii Nutrition 0.000 description 1
- 244000210789 Lilium lancifolium Species 0.000 description 1
- 235000002156 Lilium lancifolium Nutrition 0.000 description 1
- 241001634090 Lilium pumilum Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007149 gut brain axis pathway Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a combined prebiotics particle for regulating brain and intestine axis polysaccharide, and a preparation method and application thereof. The method comprises the following raw materials: astragalus extract, lily extract, soluble starch, maltodextrin, sodium citrate, potassium sorbate and xylitol. The preparation method comprises respectively processing radix astragali and Bulbus Lilii into radix astragali extract and Bulbus Lilii extract, adding soluble starch, maltodextrin, sodium citrate, potassium sorbate and xylitol, mixing, making into soft mass, sieving, granulating, drying and grading. The polysaccharide combined prebiotics granule prepared by the invention not only has the functions of tonifying qi and blood, regulating intestinal flora, inhibiting harmful bacteria and supporting beneficial bacteria, but also has the effects of soothing nerves, strengthening brain, improving learning ability, enhancing immunity of organisms and the like, and the lily and the astragalus are medicinal and edible traditional Chinese medicinal materials, so that the polysaccharide combined prebiotics granule has the effectiveness of traditional Chinese medicines and the safety of food. Its advantages are low dosage, easy carrying about, quick absorption and stable curative effect.
Description
Technical Field
The invention relates to the technical field of medicines and foods, in particular to a combined prebiotics particle for regulating brain and intestine axis polysaccharide, a preparation method and application thereof.
Background
The communication of information between the brain and the intestine is called the gut-brain axis, which is a bi-directional response system that integrates brain and gut functions via the Central Nervous System (CNS) and the Enteric Nervous System (ENS). The brain and the intestines carry out bidirectional information communication through a brain-intestine axis, exogenous information (such as vision, smell and the like) or endogenous information (such as emotion, thinking and the like) influences the perception, movement and secretion functions of the gastrointestinal tract through efferent nerve impulses of the central nervous system, and visceral induction can also influence the perception, emotion and behavior of the central nervous system through the enteric nervous system.
Sleep disorder refers to a sleep disorder syndrome in which the initiation of sleep and maintenance of sleep are disturbed, resulting in a failure of sleep quality to meet physiological needs and a significant impact on the daytime activity of the patient. With the acceleration of modern life rhythm and the increase of working pressure, more and more people suffer from sleep disorder. It is reported that 10% -15% of people who meet the standard of insomnia diagnosis among adults have high disease and have rising tendency among women, amateurs, brainworkers and the like, and it is easy to see that people face a sleep crisis, and long-term insomnia not only causes physiological damage, such as lowering of organism immune function, induction of cardiovascular and cerebrovascular diseases, but also causes emotions such as psychological anxiety and depression. Chronic insomnia can also lead to impairment of cognitive dysfunction in the patient such as memory decline, amnesia, impaired learning, etc. Learning and memory are the core content of cognitive function, and patients with various nervous system diseases are basically accompanied by the condition of cognitive dysfunction, such as senile dementia, Alzheimer disease, Parkinson disease and the like. This will not only further affect our quality of life, but may even cause organic changes leading to other diseases. More and more researches show that the neuroinflammation plays an important role in the onset of insomnia and cognitive dysfunction, and the intestinal flora can regulate the neuroinflammation of the insomnia and the cognitive dysfunction by influencing the brain-intestine axis.
The study on the mechanism for treating intestinal flora imbalance and insomnia memory decline is carried out at home and abroad, but the study on the medicines for improving insomnia and cognitive dysfunction by influencing the brain-intestine axis and improving the intestinal flora and the insomnia and cognitive dysfunction is less. Currently, the clinical treatment of the intestinal dysbacteriosis mainly uses antibiotics, and the antibiotics can kill pathogenic bacteria and influence normal flora, so that the dysbacteriosis is caused, the side effect is great, and the long-term use is not suitable; the medicines for treating insomnia are mainly sedative hypnotic medicines, which are easy to generate drug resistance after long-term administration and have side effects such as dizziness, somnolence and the like, and the medicines mainly adopt a passive treatment method clinically and lack an active prevention means.
At present, the medicines sold in the market for treating the intestinal flora imbalance, the insomnia and the cognitive dysfunction only can singly treat one disease, no medicine capable of treating the diseases simultaneously exists, the side effect of the medicines sold in the market is large, the medicines are easy to generate drug resistance after being used for a long time, and rebound or withdrawal symptoms can occur after the medicines are stopped suddenly. The feedback information of most consumers proves that some nerve-soothing and brain-strengthening medicines such as syrup and oral liquid sold in the market at present have poor effect, bad taste and inconvenient carrying.
The granule containing Chinese medicinal components not only can retain effective components of the medicine, but also has the advantages of convenient administration, high solubility, and absorption promoting effect.
Therefore, according to a reasonable compatibility principle of a traditional Chinese medicine prescription, the polysaccharide combined prebiotics particle for regulating the brain intestinal axis has the effects of simultaneously regulating intestinal flora, insomnia and cognitive dysfunction, and has the advantages of small dosage, good curative effect, small side effect and the like, so that the problem to be solved by the technical personnel in the field is urgently needed.
Disclosure of Invention
In view of the above, the invention provides polysaccharide combined prebiotic particles for regulating the brain intestinal axis, and a preparation method and application thereof, and the prepared polysaccharide combined prebiotic particles have the advantages of good solubility, good taste, stable curative effect, small side effect, convenient administration, easy absorption by organism after dissolution, wide application range, and long-term administration
In order to achieve the purpose, the invention adopts the following technical scheme:
the combined prebiotics particles for regulating the brain intestinal axis polysaccharide comprise the following components in percentage by mass:
preferably: the paint comprises the following components in percentage by mass:
preferably: the paint comprises the following components in percentage by mass:
the intestinal flora is combined according to a certain proportion, the bacteria are mutually restricted and dependent, an ecological balance is formed on quality and quantity, when the intestinal flora of a human body is in a stable state, the intestinal flora can play an important biological role in human immunity and metabolism and form a mutual benefiting symbiotic relationship with the human body, the relationship is mainly mediated through a brain intestinal axis, and the intestinal flora can enhance the intestinal barrier function by stimulating the regeneration of intestinal epithelial cells and generating mucus, so that the invasion of pathogenic microorganisms is inhibited; in addition, the occurrence of central nervous system diseases can be influenced by the direct synthesis of various neurotransmitters and neuromodulators (e.g. serotonin, short chain fatty acids); conversely, the well-established nervous system may also affect the motility, digestion and absorption of the gut flora through the vagus nerve. Once the internal and external environments of the organism change, particularly if broad-spectrum antibiotics are applied for a long time, sensitive enterobacteria are inhibited, and bacteria which are not inhibited multiply by the organism, so that flora imbalance is caused, the brain function of the host can be influenced, and the perception, the emotion and the behavior of the host are further influenced.
Insomnia and memory decline are themselves associated with the levels of monoamine neurotransmitters, such as 5 hydroxytryptamine (5HT), and cholinergic, such as acetylcholine (Ach), wherein the hippocampus plays a very important role in the cognitive process, and any factor that can cause brain damage may cause impairment of cognitive function.
There are many causes that intestinal dysbacteriosis affects insomnia and cognitive dysfunction, wherein LPS can cause an increase in the incidence of neuroinflammation, for example, up to 60% of LPS is released due to rapid growth of bacteria, in neuroinflammation, there are various methods for regulating immune cell function, humoral immunity mainly based on SIgA plays a leading role in the intestinal mucosal system, it is the first line of defense for preventing adhesion and quantification of pathogenic bacteria in intestinal mucosa, and it has a resistance effect against various endogenous symbiotic bacteria and pathogens invaded by exogenous sources.
The Astragalus root in the invention is dried root of Astragalus mongholicus Astragalus membrane aceus (Fisch.) of Leguminosae or Astragalus membranaceus A. Sweet taste and mild nature, has the effects of invigorating qi, consolidating exterior, promoting urination, tonifying heart, lowering blood pressure, resisting bacteria, etc., and can be used for treating exterior deficiency, spontaneous perspiration, internal injury due to qi deficiency, spleen deficiency, diarrhea, edema, carbuncle, cellulitis, etc.
The astragalus polysaccharide is one of the main active ingredients in astragalus, has the characteristics of wide sources, small cytotoxicity, less side effect, stable property, difficult inactivation and the like, and has the functions of enhancing the body immunity, regulating the micro-ecology and resisting bacteria, a micro-ecosystem in an organism plays an important role in the pharmacological action of oral Chinese herbal medicines, and meanwhile, the traditional Chinese medicine is beneficial to maintaining the intestinal micro-ecological balance, and the astragalus polysaccharide has the theoretical commonality and also has the interaction and mutual influence in the process of disease treatment.
The lily is dried fleshy scaly leaves of Lilium brownii var. viridumum baker, Lilium lancifolium Thunb, and Lilium pumilum DC, has effects of nourishing yin, moistening lung, clearing heart fire, tranquilizing, relieving cough and eliminating phlegm, and can be used for treating symptoms such as yin deficiency, dry cough, cough with blood, pulmonary abscess, senile chronic bronchitis, neurasthenia, insomnia, palpitation, absentmindedness, etc. The Bulbus Lilii polysaccharide has antifatigue, antidepressant, and immunoregulatory effects.
Insomnia causes a decrease in the perception and a decrease in the responsiveness of the central nervous system to the external environment, and complex physiological functions such as learning and memory are generally accomplished by synaptic transmission between neurons mediated by the binding of neurotransmitters to relevant receptors. Insomnia causes central neurotransmitter disorder, and neurotransmitters related to learning and memory mainly comprise monoamine neurotransmitters such as 5-HT, Dopamine (DA) and the like and cholinergic neurotransmitters such as Ach are in great relation. The lily polysaccharide improves learning and memory ability through behavior Morris water maze experiment, and improves the content of 5-HT and Ach in hippocampal tissue, thereby improving insomnia and cognitive dysfunction.
The astragalus and the lily are compatible and synergistic, so that the intestinal flora can be adjusted, and the effects of improving insomnia and cognitive dysfunction can be achieved. The intestine and the brain are mutually influenced by the brain-intestine axis, the two have correlation, the astragalus polysaccharide has the function of micro-ecological regulation, and the beneficial bacteria and the harmful bacteria are supported and inhibited by regulating the intestinal flora to achieve a balance and reduce the neuroinflammation so as to improve the central nervous system diseases. The Bulbus Lilii polysaccharide can improve insomnia and cognitive dysfunction to improve central nervous system, and the improved nervous system can also influence the movement, digestion and absorption of intestinal flora via vagus nerve. The compatibility of the astragalus and the lily can improve the capability of regulating intestinal flora and improve the symptoms of insomnia, cognitive dysfunction and the like.
According to traditional Chinese medicine, the astragalus membranaceus is warm in nature and is used for tonifying qi, strengthening exterior, promoting urination, expelling toxin, treating edema due to asthenia and chronic nephritis. The lily is cold in nature, has the effects of moistening lung for arresting cough, clearing heart fire and tranquilizing, can balance the cold nature of the lily, can also tonify lung qi, calm mind, promote urination, expel toxin, tonify qi and blood, tonify kidney and liver, tranquilize mind and nourish heart and the like by matching the lily and the lily.
According to the compatibility principle of a traditional Chinese medicine prescription, astragalus and lily are used as raw materials, soluble starch, maltodextrin and the like are used as auxiliary materials, and wet granulation is adopted to prepare the polysaccharide combined prebiotics particle for regulating the brain and intestine axis. The invention has balanced nutrition, and ensures the safety and nutrition of food while exerting the effectiveness of the medicine.
According to the technical scheme, the invention discloses a combined prebiotics particle for regulating the brain and intestine axis polysaccharide, and a preparation method and application thereof. Concentrating to obtain radix astragali and Bulbus Lilii extract, adding adjuvants, and making into soft mass by holding with hand and making into mass and dispersing under light pressure.
Compared with the prior art, the method has the following technical advantages:
the invention takes the astragalus and the lily as raw materials, has balanced nutrition, not only can exert the effectiveness of the medicine, but also can meet the requirement of food safety.
The astragalus and lily extract raw materials supplement each other, and have the functions of promoting urination, expelling toxin, tonifying qi and blood, tonifying kidney, benefiting liver, calming the nerves, nourishing heart and the like from the perspective of traditional Chinese medicine.
The astragalus extract has correlation with the lily extract by regulating intestinal flora, the lily extract has correlation with the central nervous system, and the brain and the intestine are mutually influenced by the brain-intestine axis, so that the prebiotic granules have the effects of regulating the intestinal flora, resisting inflammation, improving memory and improving sleep.
The prebiotic granules can be eaten as daily food, and can treat intestinal flora imbalance and improve sleep and cognitive dysfunction from the aspect of prevention.
Further: a preparation method of polysaccharide combined prebiotics granules for regulating the brain intestinal axis comprises the following steps:
(1) crushing astragalus and lily, sieving the crushed astragalus and lily by a 40-60-mesh sieve, and carrying out water extraction, filtration and concentration to obtain astragalus extract and lily extract;
(2) mixing radix astragali extract and Bulbus Lilii extract, adding soluble starch, maltodextrin, sodium citrate, potassium sorbate and xylitol, mixing to obtain soft material, sieving, granulating, drying, and grading.
Preferably: the specific operation of the step (1):
(11) radix astragali extract: uniformly mixing radix astragali powder and water according to the proportion of 1g (10-15) mL by adopting a hot water extraction method, wherein the extraction temperature is 85-95 ℃, the extraction time is 3-4 h, and filtering to obtain an extracting solution; repeating the steps for 2-3 times, combining the extracting solutions, refrigerating the extracting solutions for 12-24 hours at 4 ℃, centrifuging the extracting solutions to obtain supernate, and concentrating the supernate to the density of 1.2-1.3 g/cm3Obtaining astragalus extract;
(12) lily extract extractum: uniformly mixing lily powder and water according to a ratio of 1g (8-10) mL by adopting a hot water extraction method, wherein the extraction temperature is 80-90 ℃, the time is 1.5-2.5 h, and filtering to obtain an extracting solution; repeating the steps for 2-3 times, combining the extracting solutions, refrigerating the extracting solutions for 12-24 hours at 4 ℃, centrifuging the extracting solutions to obtain supernate, and concentrating the supernate to the density of 1.2-1.3 g/cm3To obtain lily extract.
The concentration temperature of the astragalus extract and the lily extract is preferably 55-60 ℃, and more preferably 58 ℃.
Preferably: filtering in the step (11) and the step (12) by adopting 6-8 layers of 21S multiplied by 32S gauze with the warp and weft density of 28 multiplied by 26; more preferably 8 layers of 21 sx 32S, 28 × 26 thread count gauze.
Preferably: and (3) centrifuging in the steps (11) and (12) at a stirring speed of 3500-4000 r/min, at a temperature of 25 ℃ and for 10-15 min.
Preferably: sieving the soft material in the step (2) with a 14-16-mesh sieve for granulation, and drying at the temperature of 60-80 ℃ for 60-80 min to obtain granules; further preferably, the mixture is granulated with a 15-mesh sieve and dried at 70 ℃ for 70 min.
The selection of auxiliary materials is extremely important for preparing soft materials, and a large amount of experimental researches find that maltodextrin has good dissolubility and is better auxiliary material selection, but the viscosity of the auxiliary material selection is higher, and because the traditional Chinese medicine extract has stronger viscosity, the traditional Chinese medicine extract is easy to agglomerate to cause that the granules cannot be granulated when the extract is directly mixed, so that the auxiliary material can not be independently prepared from maltodextrin, and the requirements of people can be just met by jointly using soluble starch and maltodextrin. The auxiliary materials comprise the following components in percentage by mass: 46-54% of soluble starch, 8-12% of maltodextrin, 16-22% of astragalus extract and 16-22% of lily extract are mixed according to the proportion to prepare a soft material, so that the effects of regulating intestinal flora and benefiting intelligence and soothing nerves can be ensured, the forming rate of the granules can reach more than 85%, and the corresponding indexes of moisture absorption rate, moisture content, solubility and the like can reach the production quality specification of the granules. 0.08-0.12% of sodium citrate, 0.06-0.08% of potassium sorbate and 1.5-2% of xylitol are added according to national food safety standard of the people's republic of China.
Further: the application of the prebiotic particles prepared by the method in preparing medicines, health-care foods and functional foods for improving the intestinal flora, insomnia and cognitive dysfunction by influencing the brain-intestine axis.
Compared with the prior art, the invention also has the following technical advantages:
the preparation method is simple and has lower requirements on process equipment.
The invention adopts the matching use of the soluble starch and the maltodextrin, and solves the problem that the maltodextrin has larger viscosity and is easy to agglomerate when being directly mixed with extract so as to cause the problem of incapability of granulating.
The invention uses xylitol to replace sugar as a flavoring agent, has good taste and small sugar intake.
The invention has the remarkable advantages of good yield, good taste, good dissolubility, good stability, quick absorption, stable curative effect, small side effect and the like.
The invention has large audience population and wide market.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the provided drawings without creative efforts.
FIG. 1 is a schematic diagram of the change of body weight of a mouse provided by the present invention.
FIG. 2 is a schematic structural diagram (400X) of a pathological section of a mouse hippocampal tissue CA1 region provided by the invention
Wherein, A: blank group B: model group C: positive group D: lily extract group E: astragalus extract group F: prebiotic granule group
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Statistical treatment in the examples:
analyzing the difference among the groups by single factor by using SPSS17.0 statistical analysis software, comparing the mean values among the experimental groups by adopting LSD test, and measuring data by adopting
Shows that P < 0.05 is a significant difference, and P < 0.01 is an extremely significant difference.
Example 1
A composite prebiotics granule for regulating brain intestine axis polysaccharide comprises radix astragali extract 16g, Bulbus Lilii extract 16g, soluble starch 54g, maltodextrin 12g, sodium citrate 0.12g, potassium sorbate 0.08g, and xylitol 1.8 g.
The preparation method of the polysaccharide combined prebiotics particle for regulating the brain and intestine axis comprises the following steps:
(1) pulverizing radix astragali and Bulbus Lilii, and sieving with 40 mesh sieve.
(2) Radix astragali extract: by adopting a hot water extraction method, 1000g of radix astragali powder and drinkable water are filtered according to a material-liquid ratio of 1:10(g/mL), the extraction time is 3h, the extraction temperature is 85 ℃, 6 layers of gauze (21S multiplied by 32S, the density of warp and weft is 28 multiplied by 26) are extracted for 2 times, the extracting solutions are combined, refrigerated at 4 ℃ for 12h, centrifuged at 3500r/min and 25 ℃ for 10min, and the supernatant is taken.
(3) Lily extract extractum: by adopting a hot water extraction method, 1000g of lily powder and drinkable water are filtered according to a material-liquid ratio of 1:8(g/mL), the extraction time is 1.5h, the extraction temperature is 80 ℃, 8 layers of gauze (21S multiplied by 32S, warp and weft density is 28 multiplied by 26) are extracted for 2 times, the extracting solutions are combined, refrigerated at 4 ℃ for 12h, centrifuged at 3500r/min and 25 ℃ for 10min, and the supernatant is taken.
(4) Heating the supernatant at 55 deg.C to concentrate to relative density (reference ratio is water density 1 g/cm)3) Is 1.2g/cm3108.2g of astragalus extract and 115.3g of lily extract are obtained.
(5) Mixing the extracts of radix astragali and Bulbus Lilii, adding soluble starch, maltodextrin, sodium citrate, potassium sorbate and xylitol, and mixing to obtain soft material;
(6) sieving the soft material with 14 mesh sieve, granulating, and drying at 60 deg.C for 60min to obtain granule.
Example 2
A composite prebiotics granule for regulating brain and intestine axis polysaccharide comprises radix astragali extract 19g, Bulbus Lilii extract 19g, soluble starch 49g, maltodextrin 11g, sodium citrate 0.11g, potassium sorbate 0.075g, and xylitol 1.815 g.
The preparation method of the polysaccharide combined prebiotics particle for regulating the brain and intestine axis comprises the following steps:
(1) pulverizing radix astragali and Bulbus Lilii, and sieving with 40 mesh sieve.
(2) Radix astragali extract: by adopting a hot water extraction method, 1000g of radix astragali powder and drinkable water are filtered according to a material-liquid ratio of 1:12(g/mL), the extraction time is 3h, the extraction temperature is 90 ℃, 8 layers of gauze (21S multiplied by 32S, warp and weft density is 28 multiplied by 26) are extracted for 2 times, the extracting solutions are combined, refrigerated at 4 ℃ for 12h, centrifuged at 3500r/min and 25 ℃ for 10min, and the supernatant is taken.
(3) Lily extract extractum: by adopting a hot water extraction method, 1000g of lily powder and drinkable water are filtered according to a material-liquid ratio of 1:9(g/mL), the extraction time is 1.5h, the extraction temperature is 85 ℃, 8 layers of gauze (21S multiplied by 32S, warp and weft density is 28 multiplied by 26) are extracted for 2 times, the extracting solutions are combined, refrigerated at 4 ℃ for 12h, centrifuged at 3500r/min and 25 ℃ for 10min, and the supernatant is taken.
(4) Heating the supernatant at 58 deg.C to concentrate to relative density (reference ratio is water density 1 g/cm)3) Is 1.25g/cm3110.3g of astragalus extract and 115.9g of lily extract are obtained.
(5) Mixing the extracts of radix astragali and Bulbus Lilii, adding soluble starch, maltodextrin, sodium citrate, potassium sorbate and xylitol, and mixing to obtain soft material;
(6) sieving the soft material with 15 mesh sieve, granulating, and drying at 65 deg.C for 70min to obtain granule.
Example 3
A composite prebiotics granule for regulating brain and intestine axis polysaccharide comprises 20g of radix astragali extract, 20g of lily extract, 48g of soluble starch, 10g of maltodextrin, 0.1g of sodium citrate, 0.07g of potassium sorbate and 1.83g of xylitol.
The preparation method of the polysaccharide combined prebiotics particle for regulating the brain and intestine axis comprises the following steps:
(1) pulverizing radix astragali and Bulbus Lilii, and sieving with 50 mesh sieve.
(2) Radix astragali extract: by adopting a hot water extraction method, 1000g of radix astragali powder and drinkable water are filtered according to a material-liquid ratio of 1:12(g/mL), the extraction time is 3.5h, the extraction temperature is 90 ℃, 8 layers of gauze (21S x 32S, warp and weft density is 28 x 26) are extracted for 2 times, the extracting solutions are combined, refrigerated at 4 ℃ for 18h, centrifuged at 3800r/min and 25 ℃ for 13min, and the supernatant is taken.
(3) Lily extract extractum: by adopting a hot water extraction method, 1000g of lily powder and drinkable water are filtered according to a material-liquid ratio of 1:9(g/mL), the extraction time is 2h, the extraction temperature is 85 ℃, 8 layers of gauze (21S multiplied by 32S, warp and weft density is 28 multiplied by 26) are extracted for 2 times, the extracting solutions are combined, refrigerated at 4 ℃ for 18h, centrifuged at 3800r/min and 25 ℃ for 13min, and the supernatant is taken.
(4) In thatHeating the supernatant at 58 deg.C to concentrate to relative density (reference ratio is water density 1 g/cm)3) Is 1.2g/cm3112g of astragalus extract and 116.5g of lily extract are obtained.
(5) Mixing radix astragali extract and Bulbus Lilii extract, adding soluble starch, maltodextrin, sodium citrate, potassium sorbate and xylitol, and mixing to obtain soft material;
(6) sieving the soft material with 15 mesh sieve, granulating, and drying at 70 deg.C for 70min to obtain granule.
Example 4
A composite prebiotics granule for regulating brain and intestine axis polysaccharide comprises 21g of radix astragali extract, 21g of lily extract, 47g of soluble starch, 9g of maltodextrin, 0.09g of sodium citrate, 0.065g of potassium sorbate and 1.845g of xylitol.
The preparation method of the polysaccharide combined prebiotics particle for regulating the brain and intestine axis comprises the following steps:
(1) pulverizing radix astragali and Bulbus Lilii, and sieving with 60 mesh sieve.
(2) Radix astragali extract: by adopting a hot water extraction method, 1000g of radix astragali powder and drinkable water are filtered according to a material-liquid ratio of 1:15(g/mL), the extraction time is 3.5h, the extraction temperature is 90 ℃, 7 layers of gauze (21S multiplied by 32S, warp and weft density is 28 multiplied by 26) are extracted for 2 times, the extracting solutions are combined, refrigerated at 4 ℃ for 24h, centrifuged at 4000r/min and 25 ℃ for 15min, and the supernatant is taken.
(3) Lily extract extractum: by adopting a hot water extraction method, 1000g of lily powder and drinkable water are filtered according to a material-liquid ratio of 1:10(g/mL) for 2h at an extraction temperature of 85 ℃ and 8 layers of gauze (21S multiplied by 32S, warp and weft density of 28 multiplied by 26), extracted for 2 times, the extracting solutions are combined, refrigerated at 4 ℃ for 24h, centrifuged at 4000r/min and 25 ℃ for 15min, and the supernatant is taken.
(4) Heating the supernatant at 58 deg.C to concentrate to relative density (reference ratio is water density 1 g/cm)3) Is 1.2g/cm3Obtaining 114.6g of astragalus extract and 117.1g of lily extract.
(5) Mixing radix astragali extract and Bulbus Lilii extract, adding soluble starch, maltodextrin, sodium citrate, potassium sorbate and xylitol, and mixing to obtain soft material;
(6) sieving the soft material with 16 mesh sieve, granulating, and drying at 70 deg.C for 80min to obtain granule.
Example 5
A composite prebiotics granule for regulating brain and intestine axis polysaccharide comprises 22g of radix astragali extract, 22g of lily extract, 46g of soluble starch, 8g of maltodextrin, 0.08g of sodium citrate, 0.06g of potassium sorbate and 1.86g of xylitol.
The preparation method of the polysaccharide combined prebiotics particle for regulating the brain and intestine axis comprises the following steps:
(1) pulverizing radix astragali and Bulbus Lilii, and sieving with 60 mesh sieve.
(2) Radix astragali extract: by adopting a hot water extraction method, 1000g of radix astragali powder and drinkable water are filtered according to a material-liquid ratio of 1:15(g/mL), the extraction time is 4h, the extraction temperature is 95 ℃, 7 layers of gauze (21S multiplied by 32S, the density of longitude and latitude is 28 multiplied by 26) are extracted for 2 times, the extracting solutions are combined, refrigerated at 4 ℃ for 24h, centrifuged at 4000r/min and 25 ℃ for 15min, and the supernatant is taken.
(3) Lily extract extractum: by adopting a hot water extraction method, 1000g of lily powder and drinkable water are filtered according to a material-liquid ratio of 1:10(g/mL), the extraction time is 2.5h, the extraction temperature is 90 ℃, 8 layers of gauze (21S multiplied by 32S, warp and weft density is 28 multiplied by 26) are extracted for 2 times, the extracting solutions are combined, refrigerated at 4 ℃ for 24h, centrifuged at 4000r/min and 25 ℃ for 15min, and the supernatant is taken.
(4) Heating the supernatant at 60 deg.C to concentrate to relative density (reference ratio is water density 1 g/cm)3) Is 1.3g/cm3Obtaining 115.3g of astragalus extract and 118g of lily extract.
(5) Mixing radix astragali extract and Bulbus Lilii extract, adding soluble starch, maltodextrin, sodium citrate, potassium sorbate and xylitol, and mixing to obtain soft material;
(6) sieving the soft material with 16 mesh sieve, granulating, and drying at 80 deg.C for 80min to obtain granule.
The detection results of the physicochemical indexes are shown in the following table 1, and as can be seen from the table 1, the examples 1 to 5 all accord with the national standard, and all indexes of the polysaccharide combined prebiotic particles for regulating the brain intestinal axis prepared by the invention accord with the national standard.
TABLE 1 quality reference standards and index detection values
Example 4
Mouse weight change experiment:
(1) animal selection:
selecting 60 clean KM male mice, adaptively feeding for 7 days, and randomly dividing into 6 groups of 10 mice each;
(2) dose and protocol:
lincomycin hydrochloride: diluting 64 mu L of lincomycin hydrochloride to 1mL by using normal saline;
① blank group, wherein the daily gavage is performed according to 10mL/kg normal saline for 21 days;
② model group, including 10mL/kg of intragastric lincomycin hydrochloride in the first three days, and then intragastric normal saline 10mL/kg every day for 21 days;
③ positive group, including 10mL/kg of gavage lincomycin hydrochloride for the first three days, and 20mg/kg of gavage lizhu Changle for 21 days;
④ - ⑥ polysaccharide using medicines which are divided into an astragalus extract group (astragalus group), a lily extract group (lily group) and a prebiotics particle group prepared in the embodiment 1, wherein the first three days are respectively performed with 10mL/kg of intragastric lincomycin hydrochloride, the astragalus group and the lily group are respectively performed with 100mg/kg of intragastric administration every day, and the prebiotics particle group is respectively performed with 200mg/kg of intragastric administration for 21 days;
(1) weighing once every three days for 10 times (including adaptive feeding for 7 days and 28 days);
the experimental results show that:
the body weight change of the mice after the drug administration is shown in table 2, the body weight of the mice after the drug administration of the model group is slowly increased, and the body weight of the other five groups are steadily increased. The weight change (28d) of the mice is shown in figure 1, the weight of the blank group of mice steadily increases, the weight of the rest five groups of mice steadily decreases after model building (7-10d), and the weight of the mice steadily increases after administration (11-28d), and the weight of the model group of mice slowly increases.
Table 2 weight change of mice after drug administration (n ═ 10)
| Group of | Content (g) (difference between 10d and 28d) |
| Blank group | 16.2 |
| Model set | 3.7 |
| Positive group | 15.9 |
| Lily extract group | 15.8 |
| Astragalus root extract group | 15.6 |
| Prebiotic granule group | 16.1 |
Example 5
Morris water maze test;
six groups of mice were modeled and treated as in example 4, except that after two weeks of continuous gavage, a water maze experiment was performed for 7 days, wherein the astragalus extract group was prepared as in example 3. The experiment is divided into a positioning navigation experiment and a space exploration experiment, and the escape latency, the platform passing times and the time ratio of the platform quadrant of the mouse in 60s are recorded.
The result of the escape time of the mice in the latency period is shown in table 3, the average escape latency period of each group of mice in the first day of the positioning navigation has no obvious difference, and the average escape latency period is reduced along with the increase of the training days. On the sixth day of training, the latency time of the model group was high compared to the blank group, with very significant differences (P < 0.01). Compared with the model group, the positive, lily extract and astragalus extract groups have significant difference (P < 0.05), and the prebiotics particle group has significant difference (P < 0.01). In the space exploration experiment on the seventh day, the number of times that the mouse passes through the platform and the percentage of time that the mouse occupies the platform quadrant are shown in table 4, and compared with a blank group, the number of times that the mouse passes through the platform and the percentage of time that the mouse occupies the platform quadrant are both extremely obviously reduced in a model group (P < 0.01); compared with the model group, the positive, lily extract and astragalus extract group is remarkably increased (P < 0.05), and the prebiotics particle group is remarkably increased (P < 0.01). The prebiotics particles can improve the learning and memory ability of the mice with the intestinal dysbacteriosis, and the prebiotics particles of the polysaccharide combination prepared by the compatibility of the astragalus and the lily have better effects on improving the learning and memory ability of the mice and the combination ratio of the lily extract and the astragalus extract.
Table 3 mice latency escape time (n 10,)
| group of | Day one | The next day | The third day | The fourth day | The fifth day | Day six |
| Blank group | 41.03±1.29 | 33.76±2.44 | 31.26±3.11 | 20.81±1.12 | 14.33±2.22 | 7.66±0.38** |
| Model set | 42.66±0.87 | 41.56±1.99 | 44.33±2.11 | 42.36±1.18 | 38.61±2.30 | 20.44±2.21## |
| Positive group | 40.51±1.11 | 38.58±2.21 | 32.28±1.56 | 25.81±1.33 | 18.89±1.23 | 14.67±2.55* |
| Lily extract group | 43.71±1.17 | 39.61±2.44 | 32.79±3.08 | 28.66±2.45 | 20.14±3.11 | 14.71±1.12* |
| Astragalus root extract group | 40.66±0.96 | 37.91±3.56 | 32.87±2.82 | 28.44±2.81 | 22.55±1.88 | 15.06±2.46* |
| Prebiotic granule group | 41.19±2.84 | 36.51±2.28 | 29.24±3.56 | 21.22±1.12 | 14.66±2.53 | 8.99±0.86** |
Note: comparison with model group (P < 0.05) < P < 0.01) and blank group comparison # (P < 0.05) # # (P < 0.01)
Table 4 the percentage of time that the mouse spends traversing the platform and its quadrants (n 10,
)
note: comparison with model group (P < 0.05) < P < 0.01) and blank group comparison # (P < 0.05) # # (P < 0.01)
Example 6
Detecting the quantity of the fecal flora of the mice:
six groups of mouse models were constructed and treated as in example 4, except that the astragalus extract group was prepared as in example 5. Respectively taking fresh excrement after mouse molding and 0.1g of the excrement of the mouse after 21 days of continuous administration in a centrifugal tube treated by deionized water, diluting by using normal saline for 10-5, uniformly coating the diluted excrement and the urine in BBL, LBS, EMB and EC selective culture media for 5 mu L respectively, carrying out BBL and LBS anaerobic culture for 72 hours, carrying out EMB and EC aerobic culture for 24 hours, and taking logarithm as a result and counting bacterial colonies.
The quantity of the fecal flora of the mice after molding is shown in table 5, compared with the blank group, the beneficial bacteria of five groups of mice after molding are obviously reduced, the harmful bacteria are obviously increased (P is less than 0.01), and the molding success is shown.
TABLE 5 determination of faecal flora in mice after moulding (lgN, g, n ═ 10)
| Group/species | Bifidobacterium | Lactobacillus strain | Enterococcus | Enterobacter |
| Blank group | 11.56±0.32 | 11.78±0.22 | 8.01±0.36 | 7.98±0.43 |
| Model set | 7.68±0.21 | 7.33±0.17## | 11.28±0.12## | 11.26±0.11## |
| Positive group | 7.21±0.18## | 7.42±0.23## | 11.47±0.26## | 11.19±0.27## |
| Lily extract group | 7.22±0.19## | 7.37±0.18## | 11.19±0.31## | 11.21±0.45## |
| Astragalus root extract group | 7.37±0.45## | 7.25±0.17## | 11.35±0.48## | 11.14±0.13## |
| Prebiotic granule group | 7.45±0.23## | 7.48±0.39## | 11.23±0.44## | 11.13±0.27## |
Note: comparison with blank group # (P < 0.05)
The number of the fecal flora of the mice after administration is shown in table 6, compared with the model group, the positive group, the lily extract group and the astragalus extract group have obviously reduced harmful bacteria and obviously increased beneficial bacteria (P is less than 0.05), and the prebiotic particle group has obviously reduced harmful bacteria and obviously increased beneficial bacteria (P is less than 0.01). The prebiotics particles can restore the balance of the number of the flora in the intestinal tract of the mouse with the dysbacteriosis of the intestinal tract, the particles prepared by the compatibility of the lily and the astragalus can coordinate and support the beneficial bacteria and inhibit the harmful bacteria, and the effect is better than that of a positive group, a lily extract and an astragalus extract.
Table 6 detection of faecal flora in mice after administration (lgN, g, n ═ 10)
| Group/species | Bifidobacterium | Lactobacillus strain | Enterococcus | Enterobacter |
| Blank group | 11.88±0.23** | 11.41±0.36** | 7.99±0.19** | 7.97±0.22** |
| Model set | 8.06±0.35## | 8.17±0.22## | 10.99±0.32## | 11.03±0.71## |
| Positive group | 9.91±0.26* | 9.88±0.32* | 8.90±0.26* | 8.89±0.63* |
| Lily extract group | 9.69±0.43* | 9.76±0.23* | 9.01±0.42* | 8.98±0.41* |
| Astragalus root extract group | 9.83±0.39* | 9.68±0.34* | 8.94±0.25* | 8.93±0.22* |
| Prebiotic granule group | 11.58±0.12** | 11.22±0.12** | 8.01±0.13** | 8.03±0.21** |
Note: comparison with model group (P < 0.05) and blank group comparison # (P < 0.05)
Example 7
Determination of the content of SIgA in ileal tissues:
six groups of mouse models were created and processed as in example 4, except that the astragalus extract group was prepared as in example 4. After the gavage is finished, aseptically taking the ileum of the mouse, homogenizing the tissue according to the proportion of 1:9, freezing and centrifuging at 4 ℃ (5000r/min, 15min), taking supernatant, and detecting the content of SIgA in the ileum supernatant by using an enzyme-linked immunosorbent assay kit;
the content of the mouse ileum tissue SIgA is shown in the table 7, compared with the blank group, the model group mouse ileum tissue SIgA is extremely obviously reduced (P is less than 0.01), and the model building is successful; compared with the model group, the dose groups of the positive group, the lily extract group and the astragalus extract group are remarkably increased (P < 0.05), and the prebiotics particle group is remarkably increased (P < 0.01); the prebiotics particles can improve the SIgA content in ileum tissues of mice, and the combination of the lily and the astragalus can coordinate and improve the SIgA content of mice with intestinal dysbacteriosis, and has better effect than the positive group, the lily extract and the astragalus extract.
Table 7 mouse ileal tissue SIgA content (n ═ 10,
)
note: comparison with model group (P < 0.05) < P < 0.01) and blank group comparison # (P < 0.05) # # (P < 0.01)
Example 8
Measuring contents of LPS, IL6 and TNF- α:
after the gastric lavage is finished, blood is taken from eyeballs, venous blood of each group of mice is placed for 15min, and refrigerated centrifugation (5000r/min, 15min) is carried out at 4 ℃ by using a high-speed refrigerated centrifuge to collect serum;
the content of the mouse LPS is shown in the table 8, and compared with a blank group, the content of the mouse LPS in a model group is extremely remarkably increased (P < 0.01); compared with the model group, the LPS content of mice in the positive group, the lily extract and the astragalus extract group is remarkably reduced (P < 0.05), and the prebiotics particle group is remarkably reduced (P < 0.01). The prebiotics particles can improve the LPS content of mice, and the combination of the lily and the astragalus can coordinate and reduce the LPS content of mice with intestinal dysbacteriosis, and the prebiotics particles have better effect than positive groups, lily extracts and astragalus extracts.
Table 8 content of LPS in mice (n-10,
)
| group of | Content (ng/L) |
| Blank group | 22.32±1.88** |
| Model set | 39.56±3.28## |
| Positive group | 29.11±2.36* |
| Lily extract group | 30.14±2.21* |
| Astragalus root extract group | 29.88±2.13* |
| Prebiotic granule group | 23.83±1.92** |
Note: comparison with model group (P < 0.05) < P < 0.01) and blank group comparison # (P < 0.05) # # (P < 0.01)
The content of IL-6 in the mice is shown in Table 9, and compared with the blank group, the content of IL-6 in the mice in the model group is extremely remarkably increased (P < 0.01); compared with the model group, the content of IL-6 in the mice in the positive group, the lily extract and the astragalus extract group is remarkably reduced (P < 0.05), and the content of prebiotics particle group is remarkably reduced (P < 0.01). The prebiotics particles can improve the IL-6 content of the serum inflammatory factor of the mouse, and the combination of the lily and the astragalus can coordinate and reduce the IL-6 content of the mouse with the intestinal flora imbalance, and has better effect than the positive group, the lily extract and the astragalus extract.
Table 9 content of mouse IL-6 (n-10,)
| group of | Content (pg/mL) |
| Blank group | 17.56±2.56** |
| Model set | 37.88±1.66## |
| Positive group | 26.24±2.33* |
| Lily extract group | 28.47±3.22* |
| Astragalus root extract group | 28.36±1.67* |
| Prebiotic granule group | 19.33±2.87** |
Note: comparison with model group (P < 0.05) < P < 0.01) and blank group comparison # (P < 0.05) # # (P < 0.01)
The content of mouse TNF- α is shown in Table 10, compared with a blank group, the content of mouse TNF- α in a model group is remarkably increased (P < 0.01), compared with a model group, the content of mice in a positive group, a lily extract and an astragalus extract group is remarkably reduced (P < 0.05), and the content of prebiotics particles is remarkably reduced (P < 0.01), so that the prebiotics particles can improve the content of mouse serum inflammatory factor TNF- α, and the combination of lily and astragalus can coordinately reduce the content of mouse TNF- α with intestinal flora imbalance, and the effect is better than the group ratio of the positive group, the lily extract and the astragalus extract.
Table 10 mouse TNF- α content (n-10,)
| group of | Content (pg/mL) |
| Blank group | 171.38±5.46** |
| Model set | 348.17±30.17## |
| Positive group | 225.33±10.57* |
| Lily extract group | 240.88±19.87* |
| Astragalus root extract group | 237.56±13.55* |
| Prebiotic granule group | 178.56±11.32** |
Note: comparison with model group (P < 0.05) < P < 0.01) and blank group comparison # (P < 0.05) # # (P < 0.01)
Example 9
5-HT and Ach content detection:
six groups of mouse models were constructed and processed as in example 4, except that the astragalus extract group was prepared as in example 3. After the gavage is finished, taking the whole brain of the mouse aseptically, taking materials on ice, homogenizing the tissue according to the proportion of 1:9, carrying out refrigerated centrifugation (5000r/min, 15min) at 4 ℃, taking supernatant, and detecting the content of Ach in the brain supernatant by using an enzyme-linked immunosorbent assay kit;
the results of 5-HT in mouse brain are shown in Table 11, and compared with the blank group, the 5-HT content of the mouse in the model group is reduced remarkably (P is less than 0.01); compared with the model group, the positive group, the lily extract and the astragalus extract group are obviously increased (P is less than 0.05), and the content of the prebiotics particle group is obviously increased (P is less than 0.01). The prebiotics particles can improve the 5-HT content in the mouse hippocampus tissue, and the combination of the lily and the astragalus can coordinate and improve the 5-HT content of the mouse with intestinal flora dysregulation, and has better effect than the positive group, the lily extract and the astragalus extract.
Table 11 mouse brain 5-HT content (n-10,
)
| group of | Content (pg/mL) |
| Blank group | 365.88±16.05** |
| Model set | 212.36±43.18## |
| Positive group | 303.51±30.37* |
| Lily extract group | 308.77±15.79* |
| Astragalus root extract group | 302.09±11.41* |
| Prebiotic granule group | 362.56±10.44** |
Note: comparison with model group (P < 0.05) < P < 0.01) and blank group comparison # (P < 0.05) # # (P < 0.01)
The mouse Ach content is shown in Table 12, and compared with the blank group, the mouse Ach content in the model group is remarkably reduced (P < 0.01); compared with the model group, the contents of the positive group, the lily extract and the astragalus extract are remarkably increased (P < 0.05), and the content of the prebiotics particle group is remarkably increased (P < 0.01). The prebiotics particles can improve the Ach content in the mouse hippocampus tissue, and the combination of the lily and the astragalus can coordinate and improve the Ach content in the mouse with the intestinal dysbacteriosis, and has better effect than the positive group, the lily extract and the astragalus extract.
Table 12 mouse Ach content (n-10,
)
note: comparison with model group (P < 0.05) < P < 0.01) and blank group comparison # (P < 0.05) # # (P < 0.01)
Example 10
Pathological section of mouse hippocampal tissue:
six groups of mouse models were constructed and processed as in example 4, except that the astragalus extract group was prepared as in example 2. After the gastric perfusion is finished, randomly taking 1 mouse from each group, taking 6 mice in total, performing heart perfusion by using normal saline until the liver is grey white, quickly cutting off the head to take the brain, embedding by conventional paraffin, dyeing by H & E, dehydrating by alcohol, and performing transparent treatment by using a xylene solution; finally, sealing the slices by using neutral gum; the pathological morphological change of mouse brain tissue hippocampal neurons is observed under a microscope.
The pathological section of mouse hippocampal tissue is shown in fig. 2, and the blank mouse hippocampal tissue CA1 area has normal nerve morphology and cell arrangement, abundant cytoplasm and obvious nucleolus. The mouse model group has disordered nerve cell arrangement, and partial nerve cells are shriveled and vacuolated. The positive group, the astragalus extract and the lily extract group are occasionally arranged loosely, but the cone cell morphology is recovered. The cell morphology and arrangement of the brain tissue hippocampal pyramidal cell layer of the prebiotics granule group are basically recovered to be normal. The prebiotics particles can improve the hippocampal cells of mice with dysbacteriosis of intestinal tract, so that the cell morphology and arrangement of the mouse are recovered to be normal, and the prebiotics particles have better effect than positive groups, lily extract and astragalus extract.
Compared with the positive group medicament for treating dysbacteriosis, such as lizhu changle, astragalus extract and lily extract, the compatibility of astragalus and lily in the intestinal prebiotics particles has better effects on improving the learning ability of mice crossing platforms and the like, inhibiting LPS, IL-6 and TNF- α inflammatory factors, inhibiting harmful bacteria, supporting beneficial bacteria, improving the content of SIgA, improving the content of 5-HT and Ach and recovering the morphology of mouse hippocampus cells.
The embodiments in the present description are described in a progressive manner, each embodiment focuses on differences from other embodiments, and the same and similar parts among the embodiments are referred to each other.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (9)
1. The polysaccharide combined prebiotics particle for regulating the brain intestinal axis is characterized by comprising the following components in percentage by mass:
2. the polysaccharide combined prebiotic particle for regulating the brain intestinal axis of claim 1, which comprises the following components in percentage by mass:
3. the polysaccharide combined prebiotic particle for regulating the brain intestinal axis of claim 2 comprises the following components in percentage by mass:
4. the preparation method of the combined prebiotic particle for regulating the brain intestinal axis polysaccharide according to any one of claims 1 to 3, which is characterized by comprising the following steps:
(1) crushing astragalus and lily, sieving the crushed astragalus and lily by a 40-60-mesh sieve, and carrying out water extraction, filtration and concentration to obtain astragalus extract and lily extract;
(2) mixing radix astragali extract and Bulbus Lilii extract, adding soluble starch, maltodextrin, sodium citrate, potassium sorbate and xylitol, mixing to obtain soft material, sieving, granulating, drying, and grading.
5. The preparation method of the combined prebiotic particle for regulating the brain intestinal axis polysaccharide according to the claim 4, characterized in that the specific operation of the step (1) is as follows:
(11) radix astragali extract: uniformly mixing radix astragali powder and water according to the proportion of 1g (10-15) mL by adopting a hot water extraction method, wherein the extraction temperature is 85-95 ℃, the extraction time is 3-4 h, and filtering to obtain an extracting solution; repeating the steps for 2-3 times, combining the extracting solutions, refrigerating the extracting solutions for 12-24 hours at 4 ℃, centrifuging the extracting solutions to obtain supernate, and concentrating the supernate to the density of 1.2-1.3 g/cm3Obtaining astragalus extract;
(12) lily extract extractum: uniformly mixing lily powder and water according to a ratio of 1g (8-10) mL by adopting a hot water extraction method, wherein the extraction temperature is 80-90 ℃, the time is 1.5-2.5 h, and filtering to obtain an extracting solution; repeating the steps for 2-3 times, combining the extracting solutions, refrigerating the extracting solutions for 12-24 hours at 4 ℃, centrifuging the extracting solutions to obtain supernate, and concentrating the supernate to the density of 1.2-1.3 g/cm3To obtain lily extract.
6. The preparation method of the polysaccharide combined prebiotic particle for regulating the brain intestinal axis as claimed in claim 5, wherein the filtration in the steps (11) and (12) is performed by 6-8 layers of 21S x 32S gauze with a warp and weft density of 28 x 26.
7. The preparation method of the polysaccharide combined prebiotic particle for regulating the brain intestinal axis according to claim 6, wherein the centrifugal stirring speed in the steps (11) and (12) is 3500-4000 r/min, the temperature is 25 ℃, and the time is 10-15 min.
8. The preparation method of the combination prebiotics granule for regulating the brain intestine axis polysaccharide as claimed in claim 7, wherein the soft material in the step (2) is granulated through a 14-16 mesh sieve, and dried at 60-80 ℃ for 60-80 min to obtain the granule.
9. Use of a polysaccharide combined prebiotic particle for regulating the brain intestinal axis, characterized in that the prebiotic particle prepared by the method according to any one of claims 4 to 8 is used for preparing a medicament, a health food and a functional food for improving the intestinal flora and improving insomnia and cognitive dysfunction by influencing the brain intestinal axis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911176424.2A CN110801488B (en) | 2019-11-26 | 2019-11-26 | Combined prebiotics particle for regulating brain and intestine axis polysaccharide and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911176424.2A CN110801488B (en) | 2019-11-26 | 2019-11-26 | Combined prebiotics particle for regulating brain and intestine axis polysaccharide and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110801488A true CN110801488A (en) | 2020-02-18 |
| CN110801488B CN110801488B (en) | 2021-12-14 |
Family
ID=69491421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911176424.2A Active CN110801488B (en) | 2019-11-26 | 2019-11-26 | Combined prebiotics particle for regulating brain and intestine axis polysaccharide and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110801488B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116270952A (en) * | 2023-03-21 | 2023-06-23 | 佳木斯大学 | Extract for relieving gout and extraction method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451221A (en) * | 2010-10-15 | 2012-05-16 | 佳木斯大学 | Astragalus polysaccharides microecological regulator |
-
2019
- 2019-11-26 CN CN201911176424.2A patent/CN110801488B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451221A (en) * | 2010-10-15 | 2012-05-16 | 佳木斯大学 | Astragalus polysaccharides microecological regulator |
Non-Patent Citations (2)
| Title |
|---|
| 张宇等: "黄芪多糖对微生态调节作用的物质基础研究初探", 《中国微生态学杂志》 * |
| 赵芷萌等: "百合多糖的纯化及其对肠道菌群失调小鼠的调节作用", 《食品工业科技》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116270952A (en) * | 2023-03-21 | 2023-06-23 | 佳木斯大学 | Extract for relieving gout and extraction method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110801488B (en) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104351586A (en) | Cattle mixed feed and preparation method thereof | |
| CN103585433B (en) | Traditional Chinese medicine composition for treating oral ulcer | |
| CN103734426B (en) | A kind of Fructus Corni health protection tea of improving immunity and preparation method thereof | |
| CN101284122A (en) | Soft capsules for resisting the climate sickness | |
| CN105079450A (en) | Probiotics traditional Chinese medicine preparation for relieving yin-deficiency type constipation of elder people and preparing method and application of probiotics traditional Chinese medicine preparation | |
| CN105395948A (en) | traditional Chinese medicine additive for eel and preparation method thereof | |
| CN103169923A (en) | Traditional Chinese medicine composition for treating myocarditis and preparation method of traditional Chinese medicine composition | |
| CN107468747A (en) | A kind of ginseng composition for being advantageous to anticancer, anti-cancer and preparation method thereof | |
| CN110801488B (en) | Combined prebiotics particle for regulating brain and intestine axis polysaccharide and preparation method and application thereof | |
| CN104383288A (en) | Pharmaceutical composition for treating bovine pneumonia and preparation method of pharmaceutical composition for treating bovine pneumonia | |
| CN105028995A (en) | Mixed dog food and preparation method thereof | |
| CN101073656B (en) | Pear antitussive syrup with antasthmatic and lung-moistening functions | |
| CN109172757B (en) | Intestine moistening and bowel relaxing granules | |
| CN103007145B (en) | Traditional Chinese medicine composition for treating children rotavirus enteritis and preparation method of composition | |
| CN102949681B (en) | Composition for preventing or treating colds, and its preparation method | |
| CN111084878A (en) | Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof | |
| CN104432069A (en) | Gastrointestinal smoothening tablets | |
| CN104147575A (en) | Traditional Chinese medicine preparation for treating wind-cold lung-closure-type chronic bronchitis and preparation method thereof | |
| TWI749286B (en) | Composition for regulating intestinal flora balance, preparation method and application thereof | |
| CN112972631B (en) | Traditional Chinese medicine composition with functions of improving stomach health and regulating intestinal flora and preparation method thereof | |
| CN103520253A (en) | Medicine for treating strain and asthenic disease symptoms and preparation method thereof | |
| CN113893316B (en) | Application of traditional Chinese medicine composition in preparation of medicine for improving chronic fatigue symptoms of people with damp heat mass | |
| CN111265627B (en) | Sea cucumber polysaccharide composition for regulating intestinal flora and preparation method and application thereof | |
| CN106474380A (en) | There is Chinese medicine composition, preparation of liver-protecting and alcoholism-relieving effect and preparation method thereof | |
| CN107753589B (en) | A Chinese medicinal composition for treating diabetes, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |